Sodium Hyaluronate Pretreatment for Mesenchymal Stem Cell Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to enhance the secretory function of mesenchymal stem cells (MSCs) are costly, complex, and raise safety concerns, such as gene modification altering the cell genome, and require specialized equipment for hypoxia pretreatment, limiting their practical application.
Innovation Solution
Pretreating umbilical cord mesenchymal stem cells (UCMSCs) in vitro with sodium hyaluronate (HA) at a suitable concentration to enhance their secretory function, promoting cytokine secretion and activation of the PI3K-AKT signaling pathway, which is safe, simple, and cost-effective.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene modification is used to enhance paracrine function, then therapeutic effect is improved, but safety concerns arise due to genome alteration
Solution Approach 1:
The patent applies parameter changes by modifying the culture environment parameters (adding HA to the culture medium, adjusting oxygen concentration to 5-10%) to enhance paracrine function without altering the cell genome. This resolves the contradiction by achieving therapeutic improvement through environmental parameter modification rather than genetic modification, thereby maintaining safety.
2Reliability
If hypoxia pretreatment is used to enhance paracrine function, then therapeutic effect is improved, but device complexity increases due to special culture equipment requirements
Solution Approach 1:
The patent simplifies the culture system by adjusting the oxygen concentration parameter to a moderate hypoxia level (5-10%) that can be achieved in conventional incubators rather than requiring specialized hypoxia chambers. This resolves the contradiction by maintaining therapeutic improvement while reducing device complexity through parameter optimization.
Solution Approach 2:
The patent introduces HA (hyaluronic acid) as an intermediary substance added to the culture medium to enhance paracrine function. This mediator approach allows improvement of therapeutic effect without requiring complex hypoxia equipment, as HA serves as an additional functional component that works synergistically with moderate hypoxia conditions.
3Reliability
If cytokines and growth factors are used to enhance paracrine function, then therapeutic effect is improved, but cost increases
Solution Approach 1:
The patent enables MSCs to enhance their own paracrine function through self-service mechanisms by utilizing HA and moderate hypoxia conditions in the culture medium. This allows the cells to upregulate their secretory function endogenously rather than requiring external addition of expensive cytokines and growth factors, thereby resolving the contradiction between therapeutic improvement and cost reduction.
Solution Approach 2:
The patent changes the culture medium parameters by adding HA and adjusting oxygen levels to trigger endogenous upregulation of paracrine factors. This parameter modification approach is more cost-effective than directly adding expensive cytokines and growth factors, as it stimulates the cells to produce their own therapeutic factors.
Data Source
AI summary
A method for enhancing the secretory function of mesenchymal stem cells and application thereof, belonging to the field of biotechnology. The present invention finds that the secretory function of umbilical cord mesenchymal stem cells (UCMSCs) can be remarkably promoted by pretreating the UCMSCs in vitro using sodium hyaluronate (HA), including increasing the secretion of cytokines such as HGF, SCF, EGF and VEGF, promoting activation of the PI3K-AKT signaling pathway and enhancing the repair of injury.